ALLERTIN CAPSULE

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

LORATADINE

Disponibbli minn:

APOTEX INC

Kodiċi ATC:

R06AX13

INN (Isem Internazzjonali):

LORATADINE

Dożaġġ:

10MG

Għamla farmaċewtika:

CAPSULE

Kompożizzjoni:

LORATADINE 10MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

12/24

Tip ta 'preskrizzjoni:

OTC

Żona terapewtika:

SECOND GENERATION ANTIHISTAMINES

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0120416001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2012-08-02

Karatteristiċi tal-prodott

Page 2 of 20
PRODUCT MONOGRAPH
ALLERTIN
LORATADINE CAPSULES, 10 MG
HISTAMINE H
1 RECEPTOR ANTAGONIST
APOTEX INC.
DATE OF REVISION:
150 SIGNET DRIVE
SEPTEMBER 25, 2019
TORONTO, ONTARIO
CANADA M9L 1T9
CONTROL #: 231181
Page 3 of 20
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
SUMMARY PRODUCT INFORMATION
.............................................................................................
4
INDICATIONS AND CLINICAL USE
...................................................................................................
4
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................................
5
DRUG INTERACTIONS
.........................................................................................................................
6
DOSAGE AND ADMINISTRATION
.....................................................................................................
7
OVERDOSAGE
.......................................................................................................................................
7
ACTION AND CLINICAL
PHARMACOLOGY....................................................................................
8
STORAGE AND STABILITY
.................................................................................................................
9
SPECIAL HANDLING INSTRUCTIONS
..............................................................................................
9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................... 9
PART II: SCIENTIFIC INFORMATION
.....................................................................